Key Highlights
- Pharmaceutical giant Eli Lilly has agreed to purchase Merida Biosciences for a maximum of $2.88 billion in an all-cash transaction.
- The acquisition provides Lilly with access to MER511, an investigational therapy for Graves’ disease and thyroid eye disease currently in early development.
- Merida’s portfolio features additional programs, including MER769, aimed at treating food allergies, asthma, and related allergic disorders.
- This transaction marks Lilly’s second major autoimmune acquisition this year, following its $2.4 billion Orna Therapeutics deal.
- Shares of LLY declined 0.3% during premarket hours Monday after the acquisition was disclosed.
Pharmaceutical powerhouse Eli Lilly revealed plans Monday to purchase privately owned Merida Biosciences in a deal valued at up to $2.88 billion in cash. The agreement features an initial payment combined with performance-based milestone considerations, and completion is anticipated during the fourth quarter of 2026.
Shares of LLY traded 0.3% lower in premarket activity following the announcement.
Eli Lilly and Company, LLY
Merida specializes in creating biologic therapies designed to selectively neutralize damaging antibodies associated with autoimmune and allergic disorders. The company’s primary asset, MER511, is currently undergoing early-phase clinical trials for treating Graves’ disease and thyroid eye disease.
Graves’ disease triggers thyroid hyperactivity, resulting in excessive hormone production. Thyroid eye disease may cause inflammation, protruding eyes, impaired vision, and potential blindness.
According to Lilly, preliminary results demonstrated that MER511 significantly reduced thyroid-stimulating antibodies responsible for both disorders, while maintaining an encouraging safety profile in early testing.
Existing therapeutic options for Graves’ disease encompass antithyroid drugs, radioactive iodine therapy, and surgical intervention. For thyroid eye disease, two FDA-cleared treatments are currently available: Tepezza from Amgen and Lumvoa from Viridian Therapeutics.
Bolstering Immunology Capabilities
The Merida acquisition represents another strategic step in Lilly’s efforts to strengthen its immunology division. Earlier this year in February 2026, the company announced plans to acquire Orna Therapeutics, which focuses on B-cell-targeted autoimmune treatments, in a $2.4 billion cash deal.
Beyond MER511, Merida’s development portfolio includes MER769, an investigational compound targeting food allergies, asthma, and other allergic conditions, alongside additional early-stage programs addressing kidney diseases and immune-related disorders.
“Merida’s lead program is designed to do exactly that,” said Francisco Ramirez-Valle, Lilly’s senior vice president of immunology research and early clinical development, referring to therapies that change the course of disease rather than just its effects.
Aggressive Acquisition Strategy Continues
Lilly’s acquisition momentum in 2026 has accelerated compared to previous years. During the second quarter, the pharmaceutical company finalized purchases of both Kelonia Therapeutics and Ajax Therapeutics, strengthening its hematologic oncology portfolio.
In the final days of June, Lilly wrapped up its most substantial acquisition of 2026 by purchasing Centessa Pharmaceuticals for $7.8 billion, securing access to therapies targeting neurological conditions and sleep-wake disorders, including narcolepsy treatments.
According to PitchBook analytics, total biopharmaceutical mergers and acquisitions activity through early June 2026 exceeded $106 billion spanning 201 deals. As the world’s largest pharmaceutical firm by market capitalization, Lilly has emerged as one of the industry’s most aggressive acquirers.
The drugmaker has primarily financed its acquisition spree using proceeds from its highly successful GLP-1 weight-loss medication portfolio, as it seeks to develop revenue streams in therapeutic areas outside obesity and diabetes management.
Subject to standard closing requirements, the Merida transaction is scheduled to finalize in the fourth quarter of 2026.
The post Eli Lilly (LLY) Stock Edges Lower as $2.88B Merida Biosciences Acquisition Announced appeared first on Blockonomi.
Be the first to comment